Kodiak Sciences
Kodiak Sciences
KOD
NASDAQ
2.51
USD
-71.08%
About
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients.
Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 148.5K |
| Three Month Average Volume | 5.4M |
| High Low | |
| Fifty-Two Week High | 7.77 USD |
| Fifty-Two Week Low | 1.37 USD |
| Fifty-Two Week High Date | 27 Mar 2024 |
| Fifty-Two Week Low Date | 27 Oct 2023 |
| Price and Volume | |
| Current Price | 2.51 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -11.35% |
| Thirteen Week Relative Price Change | -26.25% |
| Twenty-Six Week Relative Price Change | -62.02% |
| Fifty-Two Week Relative Price Change | -8.95% |
| Year-to-Date Relative Price Change | -30.28% |
| Price Change | |
| One Day Price Change | 1.21% |
| Thirteen Week Price Change | -21.07% |
| Twenty-Six Week Price Change | -58.24% |
| Five Day Price Change | -12.54% |
| Fifty-Two Week Price Change | 14.09% |
| Year-to-Date Price Change | -17.43% |
| Month-to-Date Price Change | -13.75% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 5.06167 USD |
| Book Value Per Share (Most Recent Quarter) | 4.07692 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 5.06167 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.07692 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.67199 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.96985 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.76542 USD |
| Normalized (Last Fiscal Year) | -4.96985 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.96985 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.76542 USD |
| Including Extraordinary Items (Last Fiscal Year) | -4.96985 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.76542 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.43734 USD |
| Cash Per Share (Most Recent Quarter) | 4.16661 USD |
| Cash Flow Per Share (Last Fiscal Year) | -4.62075 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.40089 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.02617 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 16.51% |
| Tangible Book Value (5 Year) | 25.07% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 134.76% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 43.92% |
| EPS Change (Trailing Twelve Months) | 33.98% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -219,225,000 |
| Net Debt (Last Fiscal Year) | -285,507,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 11 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -195,610,000 |
| Free Cash Flow (Trailing Twelve Months) | -158,877,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -45.46% |
| Return on Assets (Trailing Twelve Months) | -39.89% |
| Return on Assets (5 Year) | -31.73% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -74.22% |
| Return on Equity (Trailing Twelve Months) | -71.50% |
| Return on Equity (5 Year) | -41.97% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -49.53% |
| Return on Investment (Trailing Twelve Months) | -44.14% |
| Return on Investment (5 Year) | -33.61% |